Despite routine supplementation, vitamin D insufficiency is often seen in cystic fibrosis (CF) patients on account of pancreatic insufficiency. Vitamin D is a crucial component of bone health and affects nearly all cells of the immune system. However, clinical benefits or harms associated with supplementation are poorly documented. In this systematic review, we included randomized controlled trials (RCTs) that compared vitamin D supplementation with placebo (i.e. ‘non-increased dose’) in CF patients. Analysing the 8 included RCTs, the intervention group had significantly higher serum 25-hydroxyvitamin D (se25OHD) levels, but there were no significant differences found in the quantitative synthesis of clinical outcomes, including bone disease-, respiratory status- and immunological status-related outcomes. Based on our current results, while a higher vitamin D dose elevates se25OHD, it does not seem to influence clinical outcomes. Future RCTs should include outcomes of past studies and apply longer follow-up periods to document long-term patient-important outcomes.

尽管常规补充，但由于胰腺功能不全，囊性纤维化 (CF) 患者经常出现维生素 D 不足。维生素 D 是骨骼健康的重要组成部分，几乎影响免疫系统的所有细胞。然而，与补充剂相关的临床益处或危害却鲜有记载。在本系统评价中，我们纳入了比较 CF 患者补充维生素 D 与安慰剂（即“非增加剂量”）的随机对照试验 (RCT)。对纳入的 8 项 RCT 进行分析，干预组的血清 25-羟基维生素 D（se25OHD）水平显着升高，但在临床结果的定量综合方面没有发现显着差异，包括骨病、呼吸状态和免疫状态相关结果。根据我们目前的结果，虽然较高的维生素 D 剂量会提高 se25OHD，但它似乎不会影响临床结果。未来的随机对照试验应包括过去研究的结果，并应用更长的随访时间来记录长期的患者重要结果。